secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-017044
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal
----------------------------------------------------------------------------

- Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.
- Cash + short-term investments $230.3M at Mar 31, up $58.5M from Dec 31; includes $115.5M from DRI royalty deal.
- Sold DRI expanded OMIDRIA royalty: DRI gets all US royalties through 2031; Omeros retains ex-US & post-2031 global; potential milestones up to $27.5M each.
- OMS906 Phase 2 PNH data at EHA June 15; Phase 3 start late 2024. Narsoplimab BLA resubmission timeline uncertain pending FDA.
- Repurchased 3.2M shares for $11.9M in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774924017044/0001437749-24-017044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774924017044/omer20240415_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer